Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | WDR5 | P61964 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.48 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.48 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | IDE | P14735 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988304 | 0.90 | WDR5 (0.59) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL23988603 | 0.90 | KMT2A (0.47) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL23988406 | 0.90 | CYP2C9 (0.58) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL4982265 | 0.89 | WDR5 (0.58) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL4988421 | 0.89 | WDR5 (0.58) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL1307379 | 0.86 | KMT2A (0.63) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL30905609 | 0.86 | KMT2A (0.63) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL23988596 | 0.86 | CYP2C9 (0.52) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL6600439 | 0.85 | CYP2C9 (0.62) | CYP2C9KMT2AWDR5ALDH1A1MAPT | |
| SCHEMBL6600434 | 0.85 | KMT2A (0.62) | CYP2C9KMT2AWDR5ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202796-A1 | CXCL10 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-06-30 | — | — | US | disclosed |
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202796-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | CYP2C9 4152/4885KMT2A 3380/4885WDR5 3395/4885 |
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | CYP2C9 4152/4885KMT2A 3380/4885WDR5 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.